Medela is spinning off its wound care business, which will combine with Medaxis to form a new standalone wound care company.
Medela’s wound care business provides wound care solutions powered by Medela’s medical vacuum technology, including its negative pressure wound therapy line of products and services. As the healthcare of choice for more than 6 million hospitals and homes across the globe, Medela provides a research-based breast milk feeding and baby products, healthcare solutions for hospitals and clinical education. The company has 20 subsidiaries in Europe, the Americas, Asia and Australia, three production and warehouse facilities in Switzerland, the United States and China and a worldwide distribution network in more than 100 countries.
Medaxis, a Swiss med-tech company that is part of Olle Larsson Holding, specializes in the development, production and sale of medical devices and systems for modern wound treatment. The company has earned breakthrough designation from the U.S. Food and Drug Administration with its technology to help support neovascularization and tissue growth, increase cellular activity and circulation and support bacterial load reduction.
The new standalone wound care company will continue to provide wound care solutions powered by Medela’s medical vacuum technology. It will also incorporate the latest technology from Medaxis.
Jeff Castillo will transition from executive vice president of Medela Americas to lead the new wound care company as CEO on December 1, 2023. The new wound care company will continue to use Medela’s Elgin, Illinois facility for shipping products. Current Medaxis employees and leadership, as well as existing Medela wound care team members, will transition under the leadership of Castillo. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 93rd Medical Devices acquisition of the year. Between January 1, 2022, and November 10, 2022, 104 Medical Devices transactions were reported.
